Open AccessThis article is
- freely available
Monoclonal Antibody Therapies against Anthrax
Laboratory of Infectious Diseases National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Laboratory of Bacterial Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
* Author to whom correspondence should be addressed.
Received: 10 June 2011; in revised form: 6 August 2011 / Accepted: 10 August 2011 / Published: 15 August 2011
Abstract: Anthrax is a highly lethal infectious disease caused by the spore-forming bacterium Bacillus anthracis. It not only causes natural infection in humans but also poses a great threat as an emerging bioterror agent. The lethality of anthrax is primarily attributed to the two major virulence factors: toxins and capsule. An extensive effort has been made to generate therapeutically useful monoclonal antibodies to each of the virulence components: protective antigen (PA), lethal factor (LF) and edema factor (EF), and the capsule of B. anthracis. This review summarizes the current status of anti-anthrax mAb development and argues for the potential therapeutic advantage of a cocktail of mAbs that recognize different epitopes or different virulence factors.
Keywords: Bacillus anthracis; anti-PA mAbs; anti-LF mAbs; anti-EF mAbs; anti-capsule mAbs; post-exposure treatment of anthrax; a cocktail of mAbs
Citations to this Article
Cite This Article
MDPI and ACS Style
Chen, Z.; Moayeri, M.; Purcell, R. Monoclonal Antibody Therapies against Anthrax. Toxins 2011, 3, 1004-1019.
Chen Z, Moayeri M, Purcell R. Monoclonal Antibody Therapies against Anthrax. Toxins. 2011; 3(8):1004-1019.
Chen, Zhaochun; Moayeri, Mahtab; Purcell, Robert. 2011. "Monoclonal Antibody Therapies against Anthrax." Toxins 3, no. 8: 1004-1019.